Development of a discovery platform based on microfluidics and fluorescent cell f

描述(申请人提供)：该项目的总体目标是开发基于微流控和功能细胞分析的发现平台，适合以经济高效和高通量的方式同时筛选数百种蛋白质或小分子化合物。这些项目的具体目标是：(1)开发一个基于微流控技术的平台，用于高通量筛选潜在的蛋白质和小分子疗法。(2)用2-脱氧葡萄糖(2-DOG)类似物建立胰岛素刺激分化的3T3-L1脂肪细胞的葡萄糖摄取实验。(3)在基于微流控技术的多孔细胞培养生物芯片中整合并进行功能性2-DOG摄取实验。这一已完成项目的成果是一种基于微流体的高性价比平台，适用于高通量筛选蛋白质和小分子治疗性化合物。 公共卫生相关性：该项目的长期目标是确定治疗糖尿病、肥胖症、癌症和神经疾病等疾病的蛋白质和小分子疗法。作为实现这一目标的第一步，正在开发一个基于微流控技术和功能细胞生物检测的平台，以经济有效和节省时间的方式筛选整个人类蛋白质组和小分子文库。目前，市场上大多数药物的安全性和有效性仍然是首要关注的问题。然而，随着更多的治疗方法的出现，不仅有可能达到安全标准，而且药物的成本也将降低。

DESCRIPTION (provided by applicant): The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screening of potential protein and small molecule therapeutics. (2) To develop an insulin stimulated glucose uptake assay in differentiated 3T3-L1 adipocytes using fluorescent 2-deoxy glucose (2-DOG) analog. (3) To integrate and perform a functional 2-DOG uptake assay in the microfluidics based multi-well cell culture biochip. The deliverable from this completed project is a cost-effective microfluidics based platform suitable for high throughput screening of proteins and small molecule therapeutic compounds. PUBLIC HEALTH RELEVANCE: The long term objective of the project is to identify protein and small molecule therapeutics to treat diseases such as diabetes, obesity, cancer and neurological disorders. As a first step towards this objective, a platform based on microfluidics technology and functional cell bioassays is being developed to screen the entire human proteome and small molecule libraries in a cost-effective and time saving manner. Presently, safety and efficacy of most of the drugs in the market is still a primary concern. However, with more therapies becoming available, it is possible that not only safety standards will be met but also the cost of drugs will be lowered.